Leo O'Connor[email protected]Financial ResultsOraSure Technologies Q1 revenues up 129% on COVID-19 rapid immunoassay salesDemand for rapid tests is tapering, and OraSure is scaling-down COVID-19 test manufacturing amid staff layoffs.May 11, 2023Financial ResultsExact Sciences shares rise on 24% Q1 revenue growth, higher 2023 guidanceThe firm is seeing a “dramatic increase in the electronic ordering rate” at health systems, which is helping grow sales, its CEO Kevin Conroy said.May 10, 2023Financial ResultsSiemens Healthineers Q2 diagnostics revenues drop 39% on decline in rapid antigen test salesThe firm is seeing a return to low- to mid-single digital revenue growth as swings in demand from COVID-19 testing to routine testing normalize, Sharon Bracken, its president of diagnostics, said in an interview.May 10, 2023Business InsightsWeek in Review: FDA approves RSV vaccine | Non-respiratory revenue rising | Latent TB screeningRecommendations by the U.S. Preventive Services Task Force may benefit Qiagen and other makers of tests for latent TB.May 4, 2023Financial ResultsQiagen Q1 net sales decline 23% on COVID headwinds; non-COVID sales riseNon-COVID product group sales rose due to underlying double-digit growth at constant exchange rates in consumables and related revenues.May 4, 2023Regulatory ApprovalFDA approves first respiratory syncytial virus vaccineArexvy is the first respiratory syncytial virus (RSV) vaccine approved for use in the U.S. It is indicated for the prevention of lower respiratory tract disease caused by the virus in individuals 60 years of age and older.May 3, 2023Business InsightsBio-Techne fiscal Q3 sales rise 1% on strength in cell therapy, prostate test productsAmong recent business highlights, the firm noted its ExoDx Prostate test increased its addressable market by approximately 50% after receiving expanded Medicare coverage.May 3, 2023Business InsightsIllumina, Icahn issue letters to sequencing firm's shareholders, escalating proxy battleCiting dissatisfaction with the way Illumina is being managed, Carl Icahn is engaged in a proxy contest with the DNA sequencing firm.May 2, 2023Financial ResultsHologic fiscal Q2 diagnostics revenue drops 53%; firm beats analyst estimatesMolecular Diagnostics revenue of $342.2 million fell 60% from $862.5 million in the prior year quarter, as COVID-19 testing demand plummeted.May 1, 2023Business InsightsWeek in Review: IVD firms' base business growth | Quest’s ctDNA acquisition | A DNA Day interviewCompanies continued to face tough comparisons with the year-ago quarter, when demand for COVID-19 testing was still high. Encouragingly, they are seeing strength in businesses other than COVID-19 testing.April 27, 2023Previous PagePage 3 of 17Next PageTop StoriesDiagnostic TechnologiesFDA said no to proficiency testing for LDT qualityInferior tests can pass through proficiency testing, among ways PT falls short for test safety and effectiveness for intended purposes.Trends and FinanceCue Health to cut 230 jobs in restructuring planFDA ClearanceLeica Biosystems, Sectra receive FDA 510(k) clearance for digital pathology systemPolicy and RegulationFDA releases LDT final ruleSponsor ContentVisit our Molecular Diagnostics Community